Table 1 Baseline demographics and clinical characteristics at randomisation, for all patients who entered the long-term extension
Abatacept 10 mg/kg + DMARDs* (nā€Š=ā€Š218)Placebo + DMARDs* (nā€Š=ā€Š99)
Age, years53.1 (12.1)52.7 (10.9)
Female, n (%)167 (77)79 (80)
Caucasian, n (%)211 (97)92 (93)
Duration of RA, years12.1 (8.6)11.0 (8.7)
Tender joints, n31.5 (13.3)32.3 (13.7)
Swollen joints, n22.4 (10.4)22.2 (10.5)
Subject pain assessment (100 mm VAS)70.6 (19.4)68.2 (19.4)
Physical function (HAQ-DI score)1.8 (0.6)1.8 (0.6)
Patient global assessment (100 mm VAS)68.6 (19.3)68.0 (21.0)
Physician global assessment (100 mm VAS)67.7 (17.8)65.1 (17.6)
DAS28 (CRP)6.5 (0.8)6.4 (0.8)
CRP level, mg/dl4.6 (3.9)3.3 (3.1)
  • *Study groups represent treatment received in the double-blind period (6 months). Data are mean (SD) standard deviation unless otherwise specified.

  • DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; VAS, visual analogue scale; HAQ-DI, Health Assessment Questionnaire Disability Index; DAS28, Disease Activity Score 28; CRP, C-reactive protein.